Is Krsnaa Diagnost. overvalued or undervalued?

Jun 09 2025 04:35 PM IST
share
Share Via
As of April 1, 2025, Krsnaa Diagnostics is considered very attractive with a PE ratio of 28.16 and strong growth potential, outperforming peers like Max Healthcare and Apollo Hospitals, and achieving a 15.42% return compared to the Sensex's 7.55%.
As of 1 April 2025, Krsnaa Diagnostics has moved from an attractive to a very attractive valuation grade. The company is currently undervalued based on its financial metrics. Key ratios include a PE ratio of 28.16, an EV to EBITDA of 12.21, and a PEG ratio of 0.77, indicating strong growth potential relative to its price.

In comparison to its peers, Krsnaa Diagnostics stands out as more reasonably priced. For instance, Max Healthcare Institute Ltd. is deemed very expensive with a PE ratio of 100.29, while Apollo Hospitals Enterprise Ltd. has a PE of 69.03, both significantly higher than Krsnaa's. Additionally, Krsnaa's return over the past year at 15.42% outperformed the Sensex's 7.55%, reinforcing its attractive valuation in the healthcare services sector.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News